Aim:To determine the therapeutic potential of Manuka honey against New Delhi metallo-β-lactamase-1-producing Klebsiella pneumoniaeST11 in vitroand in vivo. Materials & methods:Carbapenamases and metallo-β-lactamases-producing K. pneumoniaeST11 isolated from blood culture was confirmed by VITEK-2®system, matrix-assisted laser desorption ionization–time of flight and multilocus sequence typing, followed by determination of minimum inhibitory concentration (μg/ml) using VITEK-2 system. Genetic analysis of blaNDM-1was done by PCR, pulsed-field gel electrophoresis and DNA hybridization. In vitroand in vivoefficacy of Manuka honey was performed by microbroth dilution assay and BALB/cmice model respectively. Results:K. pneumoniaeST11 displayed resistance to commonly used antibiotics. blaNDM-1was located on 150 and 270kb plasmids. Minimum inhibitory concentration and minimum bactericidal concentration of Manuka honey was 30% (v/v) and substantial reduction of bacterial mean log value (>1 log) was observed in mice. Histological analysis of mice liver and kidneys demonstrated mild to moderate inflammation. Conclusion:Manuka honey can be used as an alternate therapeutic approach for management of New Delhi metallo-β-lactamase-producing pathogens.